QDEL
QuidelOrtho Corporation
Price Chart
Latest Quote
$13.67
+0.54 (+4.11%)
Current Price
| Previous Close | $13.13 |
| Open | $13.33 |
| Day High | $13.72 |
| Day Low | $13.12 |
| Volume | 2,150,325 |
Stock Information
| Shares Outstanding | 68.19M |
| Total Debt | $2.87B |
| Cash Equivalents | $140.40M |
| Revenue | $2.66B |
| Net Income | $-1.21B |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $932.17M |
| EPS (TTM) | $-17.85 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.67B |
| Sales | $2.66B |
| Income | $-1.21B |
| Book/sh | $27.19 |
| Cash/sh | $2.06 |
| Employees | 6K |
Financial Ratios
| Quick Ratio | 0.65 |
| Current Ratio | 1.43 |
| Debt/Eq | 155.27 |
Returns & Margins
| ROA | 0.51% |
| ROE | -49.95% |
| Gross Margin | 45.18% |
| Operating Margin | -4.10% |
| Profit Margin | -45.57% |
Ownership
| Insider Ownership | 0.89% |
| Institutional Ownership | 124.05% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 5.60 |
| PEG | 2.06 |
| P/S | 0.35 |
| P/B | 0.50 |
Analyst Data
| Recommendation | none |
| Target Price | $18.62 |
Technical Indicators
| SMA20 | $13.50 |
| SMA50 | $12.79 |
| SMA200 | $22.60 |
| RSI | 54.39 |
| ATR | 1.0807 |
| Shares Float | 62.12M |
| Short Float | 24.10% |
| Short Ratio | 5.38 |
| Volatility | 0.76 |
| Rel Volume | 1.29 |
Performance History
| Week | -2.98% |
| Month | +20.12% |
| Quarter | -17.50% |
| 6 Months | -52.67% |
| YTD | -52.50% |
| Year | -51.23% |
| 3 Years | -84.07% |
| 5 Years | -88.09% |
| 10 Years | -22.20% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $13.67 | 2,150,300 |
| 2026-06-17 | $13.13 | 1,484,700 |
| 2026-06-16 | $14.12 | 911,100 |
| 2026-06-15 | $14.57 | 1,339,500 |
| 2026-06-12 | $14.13 | 1,217,000 |
| 2026-06-11 | $14.09 | 2,262,300 |
| 2026-06-10 | $13.50 | 2,773,100 |
| 2026-06-09 | $13.94 | 1,908,400 |
| 2026-06-08 | $14.47 | 1,363,400 |
| 2026-06-05 | $14.33 | 1,439,700 |
| 2026-06-04 | $15.30 | 2,149,000 |
| 2026-06-03 | $13.60 | 1,822,800 |
| 2026-06-02 | $13.29 | 1,463,700 |
| 2026-06-01 | $13.27 | 1,589,400 |
| 2026-05-29 | $13.02 | 1,410,800 |
| 2026-05-28 | $13.07 | 1,997,800 |
| 2026-05-27 | $12.33 | 1,644,400 |
| 2026-05-26 | $11.99 | 1,335,400 |
| 2026-05-22 | $11.86 | 1,280,000 |
| 2026-05-21 | $12.39 | 1,859,700 |
| 2026-05-20 | $11.91 | 1,978,600 |
| 2026-05-19 | $11.38 | 2,249,900 |
About QuidelOrtho Corporation
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
đ° Latest News
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-19T11:36:00Z
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Zacks âĸ 2026-06-17T15:16:00Z
Is the Options Market Predicting a Spike in QuidelOrtho Stock?
Zacks âĸ 2026-06-12T12:34:00Z
3 Value Stocks We Approach with Caution
StockStory âĸ 2026-06-11T12:33:37Z
1 Stock Under $50 with Exciting Potential and 2 Facing Challenges
StockStory âĸ 2026-06-08T16:21:50Z
A Look At QuidelOrtho (QDEL) Valuation After Recent Share Price Rebound And Longer Term Weakness
Simply Wall St. âĸ 2026-06-08T02:09:27Z
QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-04T15:30:25Z
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
Zacks âĸ 2026-06-03T17:44:00Z
McIntyre Partnershipsâ Analysis on QuidelOrtho Corporation (QDEL)
Insider Monkey âĸ 2026-06-01T16:49:02Z
5 Insightful Analyst Questions From QuidelOrthoâs Q1 Earnings Call
StockStory âĸ 2026-05-15T16:52:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,203,200,000 | $1,246,400,000 | $1,248,300,000 | $1,178,700,000 |
| Cost Of Revenue | $1,456,000,000 | $1,496,400,000 | $1,500,700,000 | $1,329,800,000 |
| Total Revenue | $2,730,200,000 | $2,782,900,000 | $2,997,800,000 | $3,266,000,000 |
| Operating Revenue | $2,730,200,000 | $2,782,900,000 | $2,997,800,000 | $3,266,000,000 |
| Expenses | ||||
| Interest Expense | $183,100,000 | $188,300,000 | $178,900,000 | $74,500,000 |
| Total Expenses | $2,675,400,000 | $2,737,100,000 | $2,740,800,000 | $2,283,500,000 |
| Other Income Expense | $-976,900,000 | $-1,988,400,000 | $-109,400,000 | $-171,300,000 |
| Other Non Operating Income Expenses | $-5,800,000 | $-7,100,000 | $-20,600,000 | $-8,100,000 |
| Net Non Operating Interest Income Expense | $-185,600,000 | $-188,900,000 | $-176,700,000 | $-75,300,000 |
| Total Other Finance Cost | $4,700,000 | $3,200,000 | $3,300,000 | $2,100,000 |
| Interest Expense Non Operating | $183,100,000 | $188,300,000 | $178,900,000 | $74,500,000 |
| Operating Expense | $1,219,400,000 | $1,240,700,000 | $1,240,100,000 | $953,700,000 |
| Other Operating Expenses | $97,700,000 | $51,800,000 | $27,100,000 | $12,300,000 |
| Selling And Marketing Expense | - | - | - | - |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,131,800,000 | $-2,052,000,000 | $-10,100,000 | $548,700,000 |
| Net Interest Income | $-185,600,000 | $-188,900,000 | $-176,700,000 | $-75,300,000 |
| Interest Income | $2,200,000 | $2,600,000 | $5,500,000 | $1,300,000 |
| Normalized Income | $-364,631,000 | $-144,008,100 | $60,052,000 | $670,447,200 |
| Net Income From Continuing And Discontinued Operation | $-1,131,800,000 | $-2,052,000,000 | $-10,100,000 | $548,700,000 |
| Total Operating Income As Reported | $-919,200,000 | $-1,960,900,000 | $139,100,000 | $843,700,000 |
| Net Income Common Stockholders | $-1,131,800,000 | $-2,052,000,000 | $-10,100,000 | $548,700,000 |
| Net Income | $-1,131,800,000 | $-2,052,000,000 | $-10,100,000 | $548,700,000 |
| Net Income Including Noncontrolling Interests | $-1,131,800,000 | $-2,052,000,000 | $-10,100,000 | $548,700,000 |
| Net Income Continuous Operations | $-1,131,800,000 | $-2,052,000,000 | $-10,100,000 | $548,700,000 |
| Pretax Income | $-1,107,700,000 | $-2,131,500,000 | $-29,100,000 | $735,900,000 |
| Special Income Charges | $-979,100,000 | $-2,006,700,000 | $-117,900,000 | $-162,800,000 |
| Interest Income Non Operating | $2,200,000 | $2,600,000 | $5,500,000 | $1,300,000 |
| Operating Income | $54,800,000 | $45,800,000 | $257,000,000 | $982,500,000 |
| Depreciation Amortization Depletion Income Statement | $189,200,000 | $203,400,000 | $204,800,000 | $132,500,000 |
| Depreciation And Amortization In Income Statement | $189,200,000 | $203,400,000 | $204,800,000 | $132,500,000 |
| Amortization Of Intangibles Income Statement | $189,200,000 | $203,400,000 | $204,800,000 | $132,500,000 |
| Gross Profit | $1,274,200,000 | $1,286,500,000 | $1,497,100,000 | $1,936,200,000 |
| Average Dilution Earnings | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-16.69 | $-30.16 | $-0.15 | $9.56 |
| Basic EPS | $-16.69 | $-30.16 | $-0.15 | $9.66 |
| Other | ||||
| Tax Effect Of Unusual Items | $-203,931,000 | $-73,308,100 | $-18,648,000 | $-41,452,800 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $488,500,000 | $491,500,000 | $695,800,000 | $1,257,200,000 |
| Total Unusual Items | $-971,100,000 | $-1,981,300,000 | $-88,800,000 | $-163,200,000 |
| Total Unusual Items Excluding Goodwill | $-971,100,000 | $-1,981,300,000 | $-88,800,000 | $-163,200,000 |
| Reconciled Depreciation | $442,000,000 | $453,400,000 | $457,200,000 | $283,600,000 |
| EBITDA (Bullshit earnings) | $-482,600,000 | $-1,489,800,000 | $607,000,000 | $1,094,000,000 |
| EBIT | $-924,600,000 | $-1,943,200,000 | $149,800,000 | $810,400,000 |
| Diluted Average Shares | $67,800,000 | $67,200,000 | $66,800,000 | $57,400,000 |
| Basic Average Shares | $67,800,000 | $67,200,000 | $66,800,000 | $56,800,000 |
| Diluted NI Availto Com Stockholders | $-1,131,800,000 | $-2,052,000,000 | $-10,100,000 | $548,700,000 |
| Tax Provision | $24,100,000 | $-79,500,000 | $-19,000,000 | $187,200,000 |
| Other Special Charges | $5,100,000 | - | - | $24,000,000 |
| Impairment Of Capital Assets | $710,400,000 | $1,879,500,000 | $4,500,000 | $2,800,000 |
| Restructuring And Mergern Acquisition | $263,600,000 | $127,200,000 | $113,400,000 | $136,000,000 |
| Gain On Sale Of Security | $8,000,000 | $25,400,000 | $29,100,000 | $-400,000 |
| Amortization | $189,200,000 | $203,400,000 | $204,800,000 | $132,500,000 |
| Research And Development | $186,200,000 | $218,700,000 | $245,000,000 | $187,900,000 |
| Selling General And Administration | $746,300,000 | $766,800,000 | $763,200,000 | $621,000,000 |
| Write Off | - | $56,900,000 | $4,500,000 | $2,800,000 |
| Other Gand A | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-643,300,000 | $-400,600,000 | $-420,400,000 | $-666,000,000 |
| Total Assets | $5,769,300,000 | $6,423,600,000 | $8,563,100,000 | $8,855,800,000 |
| Total Non Current Assets | $4,322,000,000 | $5,204,700,000 | $7,252,600,000 | $7,280,700,000 |
| Other Non Current Assets | $244,400,000 | $270,700,000 | $179,600,000 | $122,700,000 |
| Goodwill And Other Intangible Assets | $2,563,800,000 | $3,385,100,000 | $5,426,300,000 | $5,600,600,000 |
| Other Intangible Assets | $2,563,800,000 | $2,735,600,000 | $2,934,300,000 | $3,123,800,000 |
| Current Assets | $1,447,300,000 | $1,218,900,000 | $1,310,500,000 | $1,575,100,000 |
| Other Current Assets | $28,200,000 | $5,200,000 | $3,100,000 | $900,000 |
| Hedging Assets Current | $13,700,000 | $15,100,000 | $6,900,000 | $22,000,000 |
| Assets Held For Sale Current | $32,400,000 | $42,100,000 | $0 | - |
| Prepaid Assets | $53,900,000 | $73,200,000 | $67,000,000 | $96,700,000 |
| Inventory | $577,600,000 | $533,700,000 | $577,800,000 | $524,100,000 |
| Receivables | $571,700,000 | $451,300,000 | $488,400,000 | $586,400,000 |
| Other Receivables | $74,900,000 | $56,800,000 | $80,400,000 | $93,900,000 |
| Taxes Receivable | $79,800,000 | $112,100,000 | $104,700,000 | $38,600,000 |
| Accounts Receivable | $417,000,000 | $282,400,000 | $303,300,000 | $453,900,000 |
| Allowance For Doubtful Accounts Receivable | $-97,100,000 | $-99,600,000 | $-91,800,000 | $-89,100,000 |
| Gross Accounts Receivable | $514,100,000 | $382,000,000 | $395,100,000 | $543,000,000 |
| Cash Cash Equivalents And Short Term Investments | $169,800,000 | $98,300,000 | $167,300,000 | $345,000,000 |
| Cash And Cash Equivalents | $169,800,000 | $98,300,000 | $118,900,000 | $292,900,000 |
| Non Current Deferred Assets | - | $0 | $25,900,000 | $16,400,000 |
| Non Current Deferred Taxes Assets | - | $0 | $25,900,000 | $16,400,000 |
| Investmentin Financial Assets | - | $0 | $7,400,000 | $21,000,000 |
| Debt | ||||
| Net Debt | $2,480,400,000 | $2,384,800,000 | $2,295,700,000 | $2,345,400,000 |
| Total Debt | $2,833,900,000 | $2,681,400,000 | $2,614,100,000 | $2,849,100,000 |
| Long Term Debt And Capital Lease Obligation | $2,626,300,000 | $2,308,500,000 | $2,447,600,000 | $2,617,200,000 |
| Long Term Debt | $2,471,900,000 | $2,141,300,000 | $2,274,800,000 | $2,430,800,000 |
| Current Debt And Capital Lease Obligation | $207,600,000 | $372,900,000 | $166,500,000 | $231,900,000 |
| Current Debt | $178,300,000 | $341,800,000 | $139,800,000 | $207,500,000 |
| Other Current Borrowings | $178,300,000 | $341,800,000 | $139,800,000 | $207,500,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,848,800,000 | $3,439,100,000 | $3,557,200,000 | $3,921,200,000 |
| Total Non Current Liabilities Net Minority Interest | $2,882,700,000 | $2,440,300,000 | $2,723,400,000 | $2,914,200,000 |
| Other Non Current Liabilities | $166,400,000 | $55,300,000 | $83,600,000 | $83,800,000 |
| Non Current Deferred Liabilities | $90,000,000 | $76,500,000 | $192,200,000 | $213,200,000 |
| Non Current Deferred Taxes Liabilities | $90,000,000 | $76,500,000 | $192,200,000 | $213,200,000 |
| Current Liabilities | $966,100,000 | $998,800,000 | $833,800,000 | $1,007,000,000 |
| Other Current Liabilities | $164,300,000 | $96,800,000 | $127,800,000 | $117,100,000 |
| Current Deferred Liabilities | $37,800,000 | $33,500,000 | $36,800,000 | $115,700,000 |
| Payables And Accrued Expenses | $556,400,000 | $495,600,000 | $502,700,000 | $542,300,000 |
| Interest Payable | $48,100,000 | $39,000,000 | $30,300,000 | $1,400,000 |
| Payables | $317,200,000 | $272,300,000 | $323,800,000 | $344,200,000 |
| Total Tax Payable | $37,800,000 | $26,300,000 | $29,000,000 | $60,900,000 |
| Income Tax Payable | $11,500,000 | $5,400,000 | $11,100,000 | $51,600,000 |
| Accounts Payable | $279,400,000 | $246,000,000 | $294,800,000 | $283,300,000 |
| Other Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $1,920,500,000 | $2,984,500,000 | $5,005,900,000 | $4,934,600,000 |
| Total Equity Gross Minority Interest | $1,920,500,000 | $2,984,500,000 | $5,005,900,000 | $4,934,600,000 |
| Stockholders Equity | $1,920,500,000 | $2,984,500,000 | $5,005,900,000 | $4,934,600,000 |
| Gains Losses Not Affecting Retained Earnings | $-15,400,000 | $-36,200,000 | $-30,000,000 | $-67,600,000 |
| Other Equity Adjustments | $-15,400,000 | $-36,200,000 | $-30,000,000 | $-67,600,000 |
| Retained Earnings | $-996,000,000 | $135,800,000 | $2,187,800,000 | $2,197,900,000 |
| Other | ||||
| Ordinary Shares Number | $67,931,540 | $67,256,717 | $66,700,000 | $66,400,000 |
| Share Issued | $67,931,540 | $67,256,717 | $66,700,000 | $66,400,000 |
| Tangible Book Value | $-643,300,000 | $-400,600,000 | $-420,400,000 | $-666,000,000 |
| Invested Capital | $4,570,700,000 | $5,467,600,000 | $7,420,500,000 | $7,572,900,000 |
| Working Capital | $481,200,000 | $220,100,000 | $476,700,000 | $568,100,000 |
| Capital Lease Obligations | $183,700,000 | $198,300,000 | $199,500,000 | $210,800,000 |
| Total Capitalization | $4,392,400,000 | $5,125,800,000 | $7,280,700,000 | $7,365,400,000 |
| Additional Paid In Capital | $2,931,800,000 | $2,884,800,000 | $2,848,000,000 | $2,804,300,000 |
| Capital Stock | $100,000 | $100,000 | $100,000 | $0 |
| Common Stock | $100,000 | $100,000 | $100,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $154,400,000 | $167,200,000 | $172,800,000 | $186,400,000 |
| Current Deferred Revenue | $37,800,000 | $33,500,000 | $36,800,000 | $76,400,000 |
| Current Capital Lease Obligation | $29,300,000 | $31,100,000 | $26,700,000 | $24,400,000 |
| Current Accrued Expenses | $239,200,000 | $223,300,000 | $178,900,000 | $198,100,000 |
| Goodwill | $0 | $649,500,000 | $2,492,000,000 | $2,476,800,000 |
| Net PPE | $1,513,800,000 | $1,548,900,000 | $1,613,400,000 | $1,520,000,000 |
| Accumulated Depreciation | $-944,800,000 | $-726,200,000 | $-520,600,000 | $-278,200,000 |
| Gross PPE | $2,458,600,000 | $2,275,100,000 | $2,134,000,000 | $1,798,200,000 |
| Construction In Progress | $271,100,000 | $350,900,000 | $332,800,000 | $268,400,000 |
| Other Properties | $1,061,700,000 | $909,300,000 | $771,600,000 | $615,500,000 |
| Machinery Furniture Equipment | $777,800,000 | $673,200,000 | $595,200,000 | $515,100,000 |
| Buildings And Improvements | $332,900,000 | $330,000,000 | $399,700,000 | $364,700,000 |
| Land And Improvements | $15,100,000 | $11,700,000 | $34,700,000 | $34,500,000 |
| Properties | $0 | $0 | $0 | $0 |
| Investments And Advances | - | $0 | $7,400,000 | $21,000,000 |
| Leases | - | $728,100,000 | $602,000,000 | $434,500,000 |
| Other Short Term Investments | - | $0 | $48,400,000 | $52,100,000 |
| Available For Sale Securities | - | - | $7,400,000 | $21,000,000 |
| Other Investments | - | - | - | $21,000,000 |
| Finished Goods | - | - | - | - |
| Work In Process | - | - | - | - |
| Raw Materials | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-83,000,000 | $-112,100,000 | $70,900,000 | $744,400,000 |
| Operating Activities | ||||
| Operating Cash Flow | $105,200,000 | $83,000,000 | $280,200,000 | $885,300,000 |
| Cash Flow From Continuing Operating Activities | $105,200,000 | $83,000,000 | $280,200,000 | $885,300,000 |
| Operating Gains Losses | $5,100,000 | - | - | $24,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-188,200,000 | $-195,100,000 | $-209,300,000 | $-140,900,000 |
| Investing Cash Flow | $-192,700,000 | $-149,900,000 | $-187,600,000 | $-1,644,200,000 |
| Cash Flow From Continuing Investing Activities | $-192,700,000 | $-149,900,000 | $-187,600,000 | $-1,644,200,000 |
| Net Other Investing Changes | $-4,500,000 | $-10,700,000 | $3,500,000 | $18,400,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $0 | $-7,200,000 | $-74,300,000 |
| Issuance Of Capital Stock | $6,100,000 | $5,000,000 | $11,600,000 | $26,400,000 |
| Financing Cash Flow | $155,800,000 | $48,800,000 | $-265,800,000 | $252,000,000 |
| Cash Flow From Continuing Financing Activities | $155,800,000 | $48,800,000 | $-265,800,000 | $252,000,000 |
| Net Other Financing Charges | $-5,400,000 | $-9,600,000 | $-43,800,000 | $-46,300,000 |
| Net Common Stock Issuance | $6,100,000 | $5,000,000 | $4,400,000 | $-47,900,000 |
| Common Stock Issuance | $6,100,000 | $5,000,000 | $11,600,000 | $26,400,000 |
| Other | ||||
| Repayment Of Debt | $-2,407,200,000 | $-143,000,000 | $-228,000,000 | $-2,388,300,000 |
| Issuance Of Debt | $2,559,300,000 | $198,000,000 | $0 | $2,734,500,000 |
| Interest Paid Supplemental Data | $172,400,000 | $177,500,000 | $150,000,000 | $95,100,000 |
| End Cash Position | $169,800,000 | $98,500,000 | $119,500,000 | $293,900,000 |
| Beginning Cash Position | $98,500,000 | $119,500,000 | $293,900,000 | $802,800,000 |
| Effect Of Exchange Rate Changes | $3,000,000 | $-2,900,000 | $-1,200,000 | $-2,000,000 |
| Changes In Cash | $68,300,000 | $-18,100,000 | $-173,200,000 | $-506,900,000 |
| Common Stock Payments | $0 | $0 | $-7,200,000 | $-74,300,000 |
| Net Issuance Payments Of Debt | $155,100,000 | $53,400,000 | $-226,400,000 | $346,200,000 |
| Net Short Term Debt Issuance | $3,000,000 | $-1,600,000 | $1,600,000 | $0 |
| Net Long Term Debt Issuance | $152,100,000 | $55,000,000 | $-228,000,000 | $346,200,000 |
| Long Term Debt Payments | $-2,407,200,000 | $-143,000,000 | $-228,000,000 | $-2,388,300,000 |
| Long Term Debt Issuance | $2,559,300,000 | $198,000,000 | $0 | $2,734,500,000 |
| Net Investment Purchase And Sale | $0 | $55,900,000 | $18,200,000 | $-10,300,000 |
| Sale Of Investment | $0 | $63,100,000 | $78,300,000 | $53,400,000 |
| Purchase Of Investment | $0 | $-7,200,000 | $-60,100,000 | $-63,700,000 |
| Net PPE Purchase And Sale | $-188,200,000 | $-195,100,000 | $-209,300,000 | $-140,900,000 |
| Purchase Of PPE | $-188,200,000 | $-195,100,000 | $-209,300,000 | $-140,900,000 |
| Interest Paid Cfo | $0 | $0 | $-9,700,000 | $-10,400,000 |
| Change In Working Capital | $-125,800,000 | $-158,700,000 | $-194,900,000 | $-53,200,000 |
| Change In Other Current Liabilities | $92,000,000 | $-22,600,000 | $-5,900,000 | $-75,200,000 |
| Change In Payables And Accrued Expense | $82,600,000 | $2,100,000 | $-110,500,000 | $14,900,000 |
| Change In Accrued Expense | $900,000 | $35,000,000 | $-53,900,000 | $18,200,000 |
| Change In Payable | $81,700,000 | $-32,900,000 | $-56,600,000 | $-3,300,000 |
| Change In Account Payable | $40,000,000 | $-23,400,000 | $3,000,000 | $23,500,000 |
| Change In Tax Payable | $41,700,000 | $-9,500,000 | $-59,600,000 | $-26,800,000 |
| Change In Income Tax Payable | $41,700,000 | $-9,500,000 | $-59,600,000 | $-26,800,000 |
| Change In Prepaid Assets | $-34,600,000 | $-9,500,000 | $-26,900,000 | $-26,200,000 |
| Change In Inventory | $-148,300,000 | $-134,100,000 | $-211,600,000 | $-116,900,000 |
| Change In Receivables | $-117,500,000 | $5,400,000 | $160,000,000 | $150,200,000 |
| Changes In Account Receivables | $-117,500,000 | $5,400,000 | $160,000,000 | $150,200,000 |
| Other Non Cash Items | $900,000 | $-2,000,000 | $-6,800,000 | $85,400,000 |
| Stock Based Compensation | $45,900,000 | $42,100,000 | $51,600,000 | $48,400,000 |
| Asset Impairment Charge | $862,600,000 | $1,899,500,000 | $4,500,000 | $2,800,000 |
| Deferred Tax | $6,300,000 | $-99,300,000 | $-11,600,000 | $-44,000,000 |
| Deferred Income Tax | $6,300,000 | $-99,300,000 | $-11,600,000 | $-44,000,000 |
| Depreciation Amortization Depletion | $442,000,000 | $453,400,000 | $457,200,000 | $283,600,000 |
| Depreciation And Amortization | $442,000,000 | $453,400,000 | $457,200,000 | $283,600,000 |
| Net Income From Continuing Operations | $-1,131,800,000 | $-2,052,000,000 | $-10,100,000 | $548,700,000 |
| Income Tax Paid Supplemental Data | - | $41,600,000 | $86,600,000 | $264,800,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-1,511,400,000 |
| Purchase Of Business | - | $0 | $0 | $-1,511,400,000 |
| Depreciation | - | - | - | - |
Fetched: 2026-06-17